A detailed history of Taylor Wealth Management Partners transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Taylor Wealth Management Partners holds 1,477 shares of VRTX stock, worth $602,881. This represents 0.24% of its overall portfolio holdings.

Number of Shares
1,477
Previous 1,478 0.07%
Holding current value
$602,881
Previous $386,000 7.77%
% of portfolio
0.24%
Previous 0.16%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $234 - $292
-1 Reduced 0.07%
1,477 $416,000
Q1 2022

May 11, 2022

BUY
$221.42 - $260.97 $1,107 - $1,304
5 Added 0.34%
1,478 $386,000
Q4 2021

Jan 28, 2022

SELL
$177.01 - $223.45 $44,252 - $55,862
-250 Reduced 14.51%
1,473 $323,000
Q3 2021

Oct 26, 2021

BUY
$181.39 - $202.99 $43,533 - $48,717
240 Added 16.18%
1,723 $313,000
Q2 2021

Aug 11, 2021

BUY
$187.49 - $221.1 $16,874 - $19,899
90 Added 6.46%
1,483 $299,000
Q1 2021

Apr 21, 2021

BUY
$207.02 - $241.31 $6,210 - $7,239
30 Added 2.2%
1,393 $299,000
Q4 2020

Feb 02, 2021

BUY
$207.01 - $276.09 $64,380 - $85,863
311 Added 29.56%
1,363 $322,000
Q3 2020

Oct 14, 2020

BUY
$255.65 - $303.1 $268,943 - $318,861
1,052 New
1,052 $286,000
Q1 2019

May 14, 2019

SELL
$163.73 - $194.7 $57,305 - $68,145
-350 Closed
0 $0
Q3 2018

Oct 23, 2018

SELL
$167.73 - $192.74 $83,865 - $96,370
-500 Reduced 58.82%
350 $67,000
Q4 2017

Feb 01, 2018

SELL
$137.28 - $155.55 $13,728 - $15,555
-100 Reduced 10.53%
850 $127,000
Q3 2017

Oct 13, 2017

BUY
$148.13 - $162.24 $140,723 - $154,128
950
950 $144,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Taylor Wealth Management Partners Portfolio

Follow Taylor Wealth Management Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Taylor Wealth Management Partners, based on Form 13F filings with the SEC.

News

Stay updated on Taylor Wealth Management Partners with notifications on news.